PA8540501A1 - Conjugados peg de hgf-nk4 - Google Patents

Conjugados peg de hgf-nk4

Info

Publication number
PA8540501A1
PA8540501A1 PA20028540501A PA8540501A PA8540501A1 PA 8540501 A1 PA8540501 A1 PA 8540501A1 PA 20028540501 A PA20028540501 A PA 20028540501A PA 8540501 A PA8540501 A PA 8540501A PA 8540501 A1 PA8540501 A1 PA 8540501A1
Authority
PA
Panama
Prior art keywords
hgf
peg conjugates
polyethylglestic
hepatocits
molecul
Prior art date
Application number
PA20028540501A
Other languages
English (en)
Inventor
Michael Brandt
Apollon Papadimitriou
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PA8540501A1 publication Critical patent/PA8540501A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

UN CONJUGADO QUE COMPRENDE UN FRAGMENTO N-TERMINAL DEL FACTOR DE CRECIMIENTO DE LOS HEPATOCITOS (HGF/SF) QUE CONSISTE EN EL DOMINIO HORQUILLA Y LAS CUATRO REGIONES "KRINGLE" DE LA CADENA ALPHA, Y UN GRUPO POLIETILENGLICOL, QUE TIENE UN PESO MOLECULAR EN CONJUNTO DESDE APROXIMADAMENTE 20 HASTA 40 KDA, TIENE PROPIEDADES PERFECCIONADAS Y ES UN AGENTE TERAPEUTICO DE UTILIDAD PARA EL TRATAMIENTO DE TUMORES.
PA20028540501A 2001-02-23 2002-02-20 Conjugados peg de hgf-nk4 PA8540501A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01104640A EP1234583A1 (en) 2001-02-23 2001-02-23 PEG-conjugates of HGF-NK4

Publications (1)

Publication Number Publication Date
PA8540501A1 true PA8540501A1 (es) 2002-09-30

Family

ID=8176596

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20028540501A PA8540501A1 (es) 2001-02-23 2002-02-20 Conjugados peg de hgf-nk4

Country Status (27)

Country Link
US (2) US20030012775A1 (es)
EP (2) EP1234583A1 (es)
JP (2) JP2004521139A (es)
KR (2) KR20030072629A (es)
CN (1) CN100339393C (es)
AR (1) AR032574A1 (es)
AU (1) AU2002233354B2 (es)
BG (1) BG108125A (es)
BR (1) BR0207510A (es)
CA (1) CA2438308A1 (es)
CZ (1) CZ20032511A3 (es)
EC (1) ECSP034741A (es)
GT (1) GT200200038A (es)
HR (1) HRP20030659A2 (es)
HU (1) HUP0400979A2 (es)
IL (1) IL157426A0 (es)
MA (1) MA26998A1 (es)
MX (1) MXPA03007130A (es)
NO (1) NO20033737L (es)
PA (1) PA8540501A1 (es)
PE (1) PE20020992A1 (es)
PL (1) PL367402A1 (es)
RU (1) RU2293574C2 (es)
SK (1) SK11652003A3 (es)
WO (1) WO2002074344A2 (es)
YU (1) YU65103A (es)
ZA (1) ZA200306080B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003270118A1 (en) * 2002-08-30 2004-03-19 F. Hoffmann-La Roche Ag Scatter factor/hepatocyte growth factor antagonist nk4 for the treatment of glioma
EP1608680A2 (en) * 2003-03-24 2005-12-28 Novo Nordisk A/S Glp-2 derivatives
JP2007525981A (ja) * 2004-03-03 2007-09-13 エフ．ホフマン−ラ　ロシュ　アーゲー 肝細胞成長因子のｎ末端フラグメントを組み換え発現するための方法
CN1926150B (zh) * 2004-03-03 2010-04-14 霍夫曼-拉罗奇有限公司 纯化肝细胞生长因子的n-端片段的方法
US20090202606A1 (en) * 2008-01-25 2009-08-13 Viromed Co., Ltd. Treatment and Prevention of Cardiac Conditions Using Two or More Isoforms of Hepatocyte Growth Factor
AU2009234598C1 (en) * 2008-04-09 2012-08-23 Viromed Co., Ltd. Lyophilized DNA formulations for enhanced expression of plasmid DNA
CN102399293B (zh) * 2008-06-03 2013-12-04 中国科学院遗传与发育生物学研究所 一种与纤维蛋白特异结合的重组蛋白及其应用
US10532020B2 (en) 2012-08-22 2020-01-14 Revlon Consumer Products Corporation Nail coatings having enhanced adhesion
CA2908198A1 (en) 2013-04-18 2014-10-23 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US9823255B2 (en) 2013-06-17 2017-11-21 Armo Biosciences, Inc. Method for assessing protein identity and stability
AU2014311432A1 (en) 2013-08-30 2016-03-03 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
MX2016005915A (es) 2013-11-11 2016-12-16 Armo Biosciences Inc Metodos de uso de interleucina-10 para tratar enfermedades y trastornos.
CN106573072A (zh) 2014-06-02 2017-04-19 阿尔莫生物科技股份有限公司 降低血清胆固醇的方法
CN107001438A (zh) 2014-10-14 2017-08-01 阿尔莫生物科技股份有限公司 白细胞介素‑15组合物及其用途
CN107106655A (zh) 2014-10-22 2017-08-29 阿尔莫生物科技股份有限公司 使用白细胞介素‑10治疗疾病和病症的方法
US10618970B2 (en) 2015-02-03 2020-04-14 Armo Biosciences, Inc. Method of treating cancer with IL-10 and antibodies that induce ADCC
EP3302547A1 (en) 2015-05-28 2018-04-11 Armo Biosciences, Inc. Pegylated interleukin-10 for use in treating cancer
WO2017035232A1 (en) 2015-08-25 2017-03-02 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
BR112021012472A2 (pt) * 2019-01-28 2021-11-30 Toray Industries Forma modificada por polietileno glicol de um fator de crescimento de hepatócito ou um fragmento ativo do mesmo, e, medicamento
US20220118050A1 (en) * 2019-01-28 2022-04-21 Toray Industries, Inc. Polyethylene glycol-modified form of hepatocyte growth factor or active fragment thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993023541A1 (en) 1992-05-18 1993-11-25 Genentech, Inc. Hepatocyte growth factor variants
US6472178B1 (en) 1998-02-27 2002-10-29 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding a modified ciliary neurotrophic factor and method of making thereof
GB9225448D0 (en) * 1992-12-04 1993-01-27 Erba Carlo Spa Improved synthesis of polymer bioactive conjugates
DK0690127T3 (da) * 1994-03-31 1999-05-03 Amgen Inc Sammensætninger og fremgangsmåder til stimulering af megakaryocytvækst og -differentiering
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
EP0816381B1 (en) * 1995-03-10 2004-01-14 NAKAMURA, Toshikazu Polyethylene glycol modified hepatocyte growth factor (hgf)
DE741187T1 (de) * 1995-05-05 1997-04-30 Hoffmann La Roche Rekombinante Obesitäts-(OB)-Proteine
US6025324A (en) * 1996-05-15 2000-02-15 Hoffmann-La Roche Inc. Pegylated obese (ob) protein compositions
DK1007082T3 (da) * 1997-01-15 2007-02-19 Phoenix Pharmacologics Inc Modificeret tumor nekrose faktor
US6133426A (en) * 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
EP0922446A1 (en) * 1997-12-03 1999-06-16 Applied Research Systems Ars Holding N.V. Solution-phase site-specific preparation of GRF-PEG conjugates
EA003789B1 (ru) * 1998-04-28 2003-10-30 Апплайд Резеч Системз Арс Холдинг Н.В. КОНЪЮГАТЫ ПОЛИОЛ-β-ИНТЕРФЕРОН
US6420339B1 (en) * 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
PE20010288A1 (es) * 1999-07-02 2001-03-07 Hoffmann La Roche Derivados de eritropoyetina
CZ299516B6 (cs) * 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
US6586398B1 (en) * 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
AU2002233230B2 (en) * 2000-12-20 2007-02-01 F. Hoffmann-La Roche Ag Erythropoietin conjugates

Also Published As

Publication number Publication date
RU2293574C2 (ru) 2007-02-20
JP2004521139A (ja) 2004-07-15
EP1234583A1 (en) 2002-08-28
RU2003127395A (ru) 2005-03-20
HRP20030659A2 (en) 2004-08-31
CZ20032511A3 (en) 2004-03-17
US20080085857A1 (en) 2008-04-10
ZA200306080B (en) 2004-11-23
IL157426A0 (en) 2004-03-28
CN1571679A (zh) 2005-01-26
WO2002074344A3 (en) 2003-12-04
BG108125A (bg) 2004-09-30
GT200200038A (es) 2002-09-30
AR032574A1 (es) 2003-11-12
SK11652003A3 (sk) 2004-05-04
MXPA03007130A (es) 2003-11-18
HUP0400979A2 (hu) 2004-08-30
WO2002074344A2 (en) 2002-09-26
EP1389132A2 (en) 2004-02-18
PL367402A1 (en) 2005-02-21
YU65103A (sh) 2006-03-03
KR20030072629A (ko) 2003-09-15
NO20033737D0 (no) 2003-08-22
CN100339393C (zh) 2007-09-26
PE20020992A1 (es) 2002-11-01
AU2002233354B2 (en) 2006-11-30
NO20033737L (no) 2003-10-21
CA2438308A1 (en) 2002-09-26
US7846896B2 (en) 2010-12-07
JP2010174034A (ja) 2010-08-12
KR20090020713A (ko) 2009-02-26
ECSP034741A (es) 2003-10-28
US20030012775A1 (en) 2003-01-16
MA26998A1 (fr) 2004-12-20
BR0207510A (pt) 2004-07-27

Similar Documents

Publication Publication Date Title
PA8540501A1 (es) Conjugados peg de hgf-nk4
DE60117043D1 (de) Behandlung von mukositis
CY1123084T1 (el) Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ιι
BR0210056A (pt) composições e métodos para tratamento de hiperplasia
BR0207961A (pt) Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas
CY1109340T1 (el) Μεθοδοι θεραπειας bcl-2 διαταραχης χρησιμοποιωντας bcl-2 αντιπληροφοριακα ολιγομερη
DK1329458T5 (da) Peptider som sænker blodglucoseniveauer
DE60206512D1 (de) Rapanycin29-enole
CY1110437T1 (el) Χρηση παραγωγων καστανοσπερμινης για την θεραπεια της ηπατιτιδας c
PT1017675E (pt) Derivados da camtotecina altamente lipofilos
AR045016A1 (es) Derivados de 5-carbamimidoi-2-metilsulfaniltiofen-3-sulfonil como inhibidores conjugados de la cascada de complemento y su uso en el tratamiento de enfermedades.
AR056137A1 (es) Un conjugado peptido inmunoglobulina y su uso como antiviral
ATE478662T1 (de) Arzneilösungen enthaltend modafinilverbindungen
ES2188995T3 (es) Uso de un inhibidor de la h+, k+-atpasa en el tratamiento de los polipos nasales.
CY1105165T1 (el) Φαρμακευτικη συνθεση που πepιλαμβανει συνδυασμο μετφορμινης και 4-οξοβουτανικου οξεος και η χρηση αυτης για τη θepαπεια του διαβητη
FR2746110B1 (fr) Methode de traitement par therapie genique des tumeurs humaines et virus recombinants correspondants
GT200400241A (es) Prevencion y tratamiento de enfermedades cardiacas hipertensivas mediante el uso de los estrogenos selectivos8b-vinil-estra-1,3,5,(10)-trien-3,17b-diol y 17b-fluor-9a-vinil-estra-1,3,6,(10)-trien-3, 16a-diol
UY26648A1 (es) Inhibidores de vasopeptidasa para tratar hipertensión sistólica aislada
UY26307A1 (es) Las rutas sintéticas eficientes para la preparación de los inhibidores de la proteasa del rinovirus y los intermedios claves
UY27182A1 (es) Conjugados peg de hgf-nk4
ES2184040T3 (es) Nueva composicion de abono que permite mejorar la eficacia del noitrogeno.
TR200302193T4 (tr) Kombinasyon kemoterapisi.
DE60141994D1 (de) 13-substituierte Methacyclinverbindungen
PT1150981E (pt) Composto nucleosidico terapeutico
AR047051A1 (es) Uso de simaserina en el tratamiento del cancer